Serana Europe

Company snapshot

Serana Europe - Leading Manufacturer and Supplier of Cell Culture Products Serana Europe GmbH is a leading manufacturer and supplier of cell culture products. Our product range includes animal & human sera, sterile liquid & powdered classical media, reagents, supplements, and buffer solutions for cell culture applications. Serana’s products are used in all areas where cell culture is performed. Th

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Serana Europe. Not investment advice.

• Peer + 0 momentum

  Merck KGaA, Darmstadt

  TA overlap score 32.6

• Peer + 0 momentum

  Vaccinex

  TA overlap score 22.2

Recent activity

Latest pipeline, patent, and corporate events for Serana Europe.

1. Jun 8, 2026 Clinical update

   Placebo — Phase 2

2. Jun 8, 2026 Clinical update

   Enpatoran low dose — Phase 2

3. Jun 5, 2026 Clinical update

   Atacicept 75 mg — Phase 2

4. May 26, 2026 Clinical update

   Avelumab — Phase 3

5. May 26, 2026 Clinical update

   Xevinapant (Debio 1143) — Phase 3

View all clinical trial activity →

• What is Serana Europe?

  Serono Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Systemic Lupus Erythematosus, Lupus Erythematosus, Systemic, First Line Non-Small Cell Lung Cancer, Coronavirus Disease 2019, Solid Tumors. NovaPharmaNews links 8 clinical program(

• Is Serana Europe publicly traded?

  Serana Europe appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Serana Europe develop or market?

  We link 8 drug profile(s) where Serana Europe is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/serono-europe-limited#company-drugs.

• What are the latest developments for Serana Europe?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Serana Europe focus on?

  Serana Europe focuses on Systemic Lupus Erythematosus, Lupus Erythematosus, Systemic, First Line Non-Small Cell Lung Cancer based on our analysis of their pipeline programs and drug development activities.